Dimensional Fund Advisors
SYRE icon

Dimensional Fund Advisors’s Spyre Therapeutics SYRE Stock Holding History

Dimensional Fund Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.23M Buy
47,698
+1
+0% +$73 ﹤0.01% 2581
2026
Q1 		$2.41M Sell
47,697
-29,593
-38% -$1.12M ﹤0.01% 2662
2025
Q4 		$2.53M Sell
77,290
-6,926
-8% -$181K ﹤0.01% 2688
2025
Q3 		$1.41M Buy
+84,216
New +$1.37M ﹤0.01% 2839
2022
Q3 		– Sell
-20,253
Closed -$255K – 3520
2022
Q2 		$255K Sell
20,253
-6,986
-26% -$245K ﹤0.01% 3215
2022
Q1 		$1.57M Sell
27,239
-384
-1% -$32.2K ﹤0.01% 2886
2021
Q4 		$3.28M Buy
27,623
+2,310
+9% +$365K ﹤0.01% 2702
2021
Q3 		$5.03M Buy
25,313
+1,149
+5% +$201K ﹤0.01% 2582
2021
Q2 		$4.21M Buy
24,164
+427
+2% +$77.6K ﹤0.01% 2661
2021
Q1 		$4.69M Buy
23,737
+2,135
+10% +$410K ﹤0.01% 2604
2020
Q4 		$4.25M Buy
21,602
+1,624
+8% +$337K ﹤0.01% 2578
2020
Q3 		$3.54M Buy
19,978
+29
+0.1% +$5.37K ﹤0.01% 2569
2020
Q2 		$4.61M Sell
19,949
-1,164
-6% -$222K ﹤0.01% 2501
2020
Q1 		$2.46M Sell
21,113
-113
-0.5% -$19.2K ﹤0.01% 2646
2019
Q4 		$4.05M Sell
21,226
-212
-1% -$41.6K ﹤0.01% 2682
2019
Q3 		$4.12M Buy
21,438
+654
+3% +$127K ﹤0.01% 2666
2019
Q2 		$3.56M Buy
20,784
+2,760
+15% +$477K ﹤0.01% 2747
2019
Q1 		$3.63M Buy
18,024
+6,575
+57% +$1.37M ﹤0.01% 2745
2018
Q4 		$2.14M Buy
11,449
+4,796
+72% +$1.02M ﹤0.01% 2854
2018
Q3 		$1.59M Buy
6,653
+2,979
+81% +$696K ﹤0.01% 2974
2018
Q2 		$972K Hold
3,674
– – ﹤0.01% 3032
2018
Q1 		$911K Buy
3,674
+2,227
+154% +$402K ﹤0.01% 3017
2017
Q4 		$196K Buy
1,447
+907
+168% +$111K ﹤0.01% 3225
2017
Q3 		$64K Buy
+540
New +$50.6K ﹤0.01% 3297

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Dimensional Fund Advisors's SYRE Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Spyre Therapeutics (SYRE) stake by 0% in Q2 2026, buying an estimated $73 and bringing the position to 47,698 shares worth $4.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

Dimensional Fund Advisors first reported a position in SYRE in Q3 2017 and has held it in 24 quarters since. The position peaked at $5.03M in Q3 2021. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Dimensional Fund Advisors held 47,698 shares of Spyre Therapeutics worth $4.23M as of Q2 2026.
  • Dimensional Fund Advisors bought 1 Spyre Therapeutics share in Q2 2026, an estimated $73.
  • Spyre Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2581 holding.
  • Dimensional Fund Advisors first reported a position in Spyre Therapeutics in Q3 2017 and has held it in 24 quarters since.
  • Dimensional Fund Advisors's Spyre Therapeutics position peaked at $5.03M in Q3 2021.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.